Biotricity Inc (NASDAQ:BTCY) introduces Biokit – a nifty home-use gadget that includes a digital thermometer, pulse oximeter, and blood pressure cuff. All three devices have been approved by the FDA, and can be operated via wireless and seamlessly integrated into the Biotricity ecosystem, a platform for interconnectivity. It transmits data in real-time to both the physician and patient through the web and an App. Biokit represents a crucial stage in the evolution of Bioflux solution, where other tools can be combined to create a single solution for remote cardiac monitoring.
The company expects each device within the kit to be made available to customers in the first quarter of 2022. Biotricity’s Chief Executive Officer Dr. Waqaas Al-Siddiq says that Biokit is all set to expand their total market with a customized offering for the $18.4 billion-dollar North American portable device market. With Bioflux and Biokit, the company looks forward to offering a comprehensive cardiac diagnostics and management product line for effective, precise, and affordable disease management in the long term.
In other news, Dr. Waqaas Al-Siddiq gave a talk at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. The presentation was mainly about Biokit, which addresses challenges associated with existing home-based medical devices. For those interested to see the presentation, you can visit their corporate website – it will be available for 30 days after the event.
Market Action:
As of 11:08, BTCY stock fell 0.16% to $3.16 with more than 26K shares traded hands, compared to its average volume of 133K shares.
